Literature DB >> 9157982

DNA damage-associated dysregulation of the cell cycle and apoptosis control in cells with germ-line p53 mutation.

K Goi1, M Takagi, S Iwata, D Delia, M Asada, R Donghi, Y Tsunematsu, S Nakazawa, H Yamamoto, J Yokota, K Tamura, Y Saeki, J Utsunomiya, T Takahashi, R Ueda, C Ishioka, M Eguchi, N Kamata, S Mizutani.   

Abstract

Lymphoblastoid cell lines (LCLs) with heterozygous p53 mutations at residues 286A, 133R, 282W, 132E, and 213ter were established from five independent Li-Fraumeni syndrome families. When cell cycle regulation in response to gamma-irradiation was studied, these LCLs showed an abnormal G1 checkpoint associated with defective inhibition of cyclin E/cyclin-dependent kinase 2 activity in all cases except for 282W LCL, which showed a normal G1 checkpoint. On the other hand, the control of S-phase-G2 as determined by cyclin A/cyclin-dependent kinase 2 activity was defective in all these LCLs. The mitotic checkpoint was also defective in the two LCLs analyzed as either competent or incompetent for G1 arrest. When radiation-induced apoptosis, which requires wild-type p53 function under optimal conditions, was studied, all of these LCLs showed significant failure compared to normal LCLs. These findings indicate that although p53-dependent transactivation and G1-S-phase cell cycle control are variably dysregulated, the induction of apoptosis and control of the cell cycle at S-phase-G2 and the mitotic checkpoint in response to DNA-damaging agents are consistently dysregulated in heterozygous mutant LCLs. This suggests that these dysfunctions underlie, at least in part, the susceptibility of Li-Fraumeni syndrome families to cancer. Furthermore, the approach presented is a potentially useful method for studying individual carriers of different germ-line p53 mutations and different biological features.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9157982

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  Mutational Status of CDKN2A and TP53 Genes in Laryngeal Squamous Cell Carcinoma.

Authors:  Teodora A Todorova; Stanislav H Jordanov; Gergana S Stancheva; Ivan J Chalakov; Mincho B Melnicharov; Kuncho V Kunev; Vanio I Mitev; Radka P Kaneva; Teodora E Goranova
Journal:  Pathol Oncol Res       Date:  2014-08-23       Impact factor: 3.201

2.  p53 deficiency increases transformation by v-Abl and rescues the ability of a C-terminally truncated v-Abl mutant to induce pre-B lymphoma in vivo.

Authors:  X Zou; F Cong; M Coutts; G Cattoretti; S P Goff; K Calame
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

3.  MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts.

Authors:  N V Rajeshkumar; Elizabeth De Oliveira; Niki Ottenhof; James Watters; David Brooks; Tim Demuth; Stuart D Shumway; Shinji Mizuarai; Hiroshi Hirai; Anirban Maitra; Manuel Hidalgo
Journal:  Clin Cancer Res       Date:  2011-03-09       Impact factor: 12.531

4.  The need for dynamic methods for measuring cell cycle perturbations: a study in radiation-treated lymphoblastoid cell lines of varying p53 status.

Authors:  R Gilchrist; M E Lomax; R S Camplejohn
Journal:  Cell Prolif       Date:  1999-02       Impact factor: 6.831

5.  Li-fraumeni syndrome.

Authors:  David Malkin
Journal:  Genes Cancer       Date:  2011-04

6.  Quantitative Phosphoproteomics Reveals Wee1 Kinase as a Therapeutic Target in a Model of Proneural Glioblastoma.

Authors:  Rebecca S Lescarbeau; Liang Lei; Katrina K Bakken; Peter A Sims; Jann N Sarkaria; Peter Canoll; Forest M White
Journal:  Mol Cancer Ther       Date:  2016-05-17       Impact factor: 6.261

Review 7.  Genetic and molecular alterations in pancreatic cancer: implications for personalized medicine.

Authors:  Yantian Fang; Qizhi Yao; Zongyou Chen; Jianbin Xiang; Fisher E William; Richard A Gibbs; Changyi Chen
Journal:  Med Sci Monit       Date:  2013-10-31

8.  Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor.

Authors:  Shinji Mizuarai; Kazunori Yamanaka; Hiraku Itadani; Tsuyoshi Arai; Toshihide Nishibata; Hiroshi Hirai; Hidehito Kotani
Journal:  Mol Cancer       Date:  2009-06-08       Impact factor: 27.401

9.  Number of rare germline CNVs and TP53 mutation types.

Authors:  Amanda G Silva; Isabel Maria W Achatz; Ana Cv Krepischi; Peter L Pearson; Carla Rosenberg
Journal:  Orphanet J Rare Dis       Date:  2012-12-21       Impact factor: 4.123

10.  High resolution melting for mutation scanning of TP53 exons 5-8.

Authors:  Michael Krypuy; Ahmed Ashour Ahmed; Dariush Etemadmoghadam; Sarah J Hyland; Anna DeFazio; Stephen B Fox; James D Brenton; David D Bowtell; Alexander Dobrovic
Journal:  BMC Cancer       Date:  2007-08-31       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.